Eli Lilly (LLY) closed the most recent trading day at $797.48, moving -0.3% from the previous trading session.
Eli Lilly has asked the U.S. government to pause the new law that allows Medicare to negotiate prices for its costliest prescription drugs, Bloomberg News reported on Monday, citing Lilly Chief Executive Dave Ricks.
Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market with their obesity injections Zepbound and Wegovy, are both looking to develop next-generation versions.
Eli Lilly said on Monday it would acquire cancer therapy developer Scorpion Therapeutics for $2.5 billion in cash.
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Pharmaceutical stocks represent an interesting prospect — while it is incredibly tough to separate the wheat from the chaff, picking a winner early on is more or less a ticket to outsized returns.
In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.